Front-line Therapy With Carfilzomib, Lenalidomide, and Dexamethasone Induction

Inclusion Criteria: * Patients diagnosed with multiple myeloma based on the new International Myeloma Working Group * Subjects must have symptomatic myeloma with at least one CRAB criteria * Subjects must not have been treated previously with any systemic therapy for multiple myeloma Exclusion Criteria: * Pregnant or lactating females * Evidence of mucosal or internal bleeding and/or platelet refractory * Acute active infection requiring treatment * Treatment by localized radiotherapy if the interval between the end of radiotherapy and initiation of protocol therapy lower than 2 weeks * Treatment by corticosteroids if exceed the equivalent of 160 mg of dexamethasone in a 2-week period before initiation therapy * Subjects not eligible for high dose therapy